Please find attached press release for Q1FY27 financial results
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 23 Jul 2026, 12:39 PM IST · BSE ID: c50f70d6-0133-4725-83d2-7291ab228c3f
View Original BSE Filing (PDF)
💡
In Simple Terms
Cipla reported its first-quarter financial results, showing higher total income but lower profit compared to last year.
🤖 AI Summary
- Cipla's Q1 FY27 Income from Operations totaled INR 7,119 Cr, showing 2% YoY growth.
- Net Profit after Tax (PAT) for Q1 FY27 was INR 789 Cr, a 39.2% YoY decrease.
- One-India business delivered highest quarterly revenue of INR 3,452 Cr, growing 12% YoY.
- North America segment recorded quarterly revenue of $162 Mn, translating to a 21% YoY decline in INR.
- Research and Development investments stood at INR 486 Cr, 6.8% of sales, increasing 12.3% YoY.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income from Operations
7,119 INR Cr
2%
One-India Revenue
3,452 INR Cr
12%
North America Revenue
1,532 INR Cr
-21%
R&D investments
486 INR Cr
12.3%
🏢 How This Affects the Company
The One-India business recorded its highest-ever quarterly revenue, indicating strong domestic market performance and improved chronic mix. North America experienced a revenue decline in INR terms, but the company launched new products like gVentolin, Nintedanib, and Dapagliflozin, aiming for sequential growth.
Total Income from Operations increased by 2% YoY, while PAT declined by 39.2% YoY to INR 789 Cr, impacting overall profitability. EBITDA decreased by 33% YoY to INR 1,192 Cr, with EBITDA margin contracting to 16.7% from 25.6%.
R&D investments increased by 12.3% YoY to INR 486 Cr, driven by increased product filings and development initiatives. The company's net cash position was INR 9,494 Cr, while total debt increased to INR 600 Cr from INR 459 Cr.
The significant decline in North America revenue, an important market, presents a revenue concentration risk, despite new product launches designed to mitigate this going forward. The substantial YoY decrease in PAT and EBITDA indicates a potential margin compression trend.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, specifically the 39.2% YoY decline in net profit attributable to owners to INR 789 Cr in Q1 FY27.
🔍
Management Signal
Management intends to focus on growing key markets, building flagship brands, investing in future pipelines, and addressing regulatory matters to drive future performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate North America revenue trend following new product launches.
Any updates on regulatory fronts, as mentioned by management.
Further details on product pipeline and development initiatives.
MEDIUM RISK
Significant decline in PAT and North America revenue for Q1 FY27 is a concern despite overall revenue growth.
💡 Investor Takeaway
Cipla's Q1 FY27 Income from Operations increased 2% YoY to INR 7,119 Cr, but Net Profit after Tax (PAT) declined 39.2% YoY to INR 789 Cr. One-India revenue grew 12% YoY to INR 3,452 Cr, while North America revenue decreased 21% YoY to INR 1,532 Cr.
⚖️ Strengths & Concerns
✅ Positives
- One-India business achieved highest-ever quarterly revenue of INR 3,452 Cr, with 12% YoY growth, demonstrating strong domestic performance.
- Emerging Markets and Europe delivered 5% YoY growth in USD terms, with revenue of INR 999 Cr, showing consistent international market expansion.
⚠️ Concerns
- Net Profit after Tax (PAT) declined by 39.2% YoY to INR 789 Cr in Q1 FY27 from INR 1,298 Cr in Q1 FY26.
- North America revenue decreased by 21% YoY to INR 1,532 Cr, affecting overall revenue growth despite new product introductions.
📅 Company Track Record
In Q1 FY27, Cipla's net profit attributable to owners declined to ₹789.05 Crores, compared to Q4 FY26 where PAT declined by -54.6% to INR 555 Cr, and FY26 PAT fell -26.5% to INR 3,879 Cr. This shows a continued trend of profit decline.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Cipla's total income from operations in Q1 FY27?
Cipla's Total Income from Operations in Q1 FY27 was INR 7,119 Cr, a 2% increase compared to INR 6,957 Cr in Q1 FY26.
What was Cipla's Net Profit after Tax (PAT) for Q1 FY27?
Cipla's Net Profit after Tax (PAT) for Q1 FY27 was INR 789 Cr, which is a 39.2% decline from INR 1,298 Cr in Q1 FY26.
How did Cipla's One-India business perform in Q1 FY27?
The One-India business recorded its highest-ever quarterly revenue of INR 3,452 Cr in Q1 FY27, showing a solid growth of 12% YoY.
What was Cipla's North America revenue in Q1 FY27?
Cipla's North America business delivered a quarterly revenue of $162 Mn, which translates to INR 1,532 Cr and represents a 21% YoY decline in INR terms.
What were Cipla's R&D investments in Q1 FY27?
Cipla's R&D investments in Q1 FY27 stood at INR 486 Cr, accounting for 6.8% of sales, and were up 12.3% YoY.
Questions based on this BSE filing only. For information purposes.